Official Website of ILIAS Biologics, Inc. Global Leader in Exosome Therapeutics
Location: South Korea, Gwanpyeong-dong
Total raised: $20.6M
Investors 1
| Date | Name | Website |
| - | Daedeok Ve... | dvpdvp.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.10.2020 | Series B | $20.6M | - |
Mentions in press and media 3
| Date | Title | Description |
| 28.06.2021 | ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury | DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in coll... |
| 01.02.2021 | ILIAS Biologics announces the 2nd POC study, showing anti-inflammatory effects of ILB202 on preterm birth | |
| 01.10.2020 | Ilias Biologics Raises $20.6M in Series B Financing | Ilias Biologics Inc. (previously Cellex Life Sciences, Inc.), a Daejeon, South Korea-based exosome-based therapeutics company, completed a Series B financing round of $20.6m. The initial investors from the Series A round, HB Investment, Tim... |